SP 7.04 Retrospective Audit of Cardiovascular Risk in Patients Undergoing Pancreaticoduodenectomy

Clicks: 32
ID: 324113
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #56 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Pancreatic cancer is a highly metabolic disease with high-risk of major adverse cardio-vascular events (MACE). Those undergoing surgery who take statins have longer survival. QRISK3 scoring estimates the risk of acute myocardial infarction or stroke within 10 years in the UK population, and NICE recommends its validated use to guide optimal metabolic therapy (OMT). In patients undergoing pancreaticoduodenectomy the relationship between QRISK3 score and OMT, MACE, or survival is unknown. Methods QRISK3 was retrospectively calculated in patients undergoing pancreaticoduodenectomy for invasive malignancy (2022-2024). Rates of OMT and MACE (+/- all cause mortality [ACM]) were determined. The relationship between QRISK3 and survival was explored using Cox regression. Results Data from 114 patients were reviewed; male 50 (44%), median (IQR) age 67 (59-73) years. At 1-year: in high-risk (QRISK3≥20%) patients OMT 4/46 (8.7%), MACE+ACM 7/46 (15.2%); moderate-risk (QRISK3≥10%) OMT 6/38 (15.8%), MACE+ACM 3/38 (7.9%); low-risk (QRISK3<10%) OMT 29/30 (96.7%), MACE+ACM 2/30 (6.7%). QRISK3 score independently predicted survival (median 24 months) in all cancer types (HR [95%CI] 1.033 [1.002-1.065] p=0.037). In pancreatic ductal adenocarcinoma (n=46), QRISK3 score remained a predictor of survival (HR [95%CI] 1.056 [1.001-1.140] p=0.047) after accounting for T stage, N stage, R0 resection and chemotherapy status. Conclusion Patients undergoing pancreatic surgery are at high-risk of MACE and mortality and receive sub-optimal prevention. Pre-operative cardiovascular risk assessment and mitigation with OMT could improve outcomes. QRISK3 score may predict overall survival but further work is required to validate and fully understand this relationship.
Reference Key
openalex_W7172505242 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Oscar Edginton, Yazan Khaled, J. Pine, Samir Pathak, Andrew Smith, Iestyn Shapey
Are you one of these authors? Claim your profile
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag087.091
URL
https://doi.org/10.1093/bjs/znag087.091
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.